Predictive and smart profiling/selection of clinical drug candidates HUmanized Mouse Models

TransCure bioServices is a CRO who has developed unique Research & Development (R&D) platforms, called the Humanized Immune System (HIS) mouse model.

This huMouse model have been adapted in 3 main therapeutic areas :

Oncology-Immunology

Human Immunodeficiency Virus (HIV)

Inflammatory Bowel Diseases

Others platform are also available in inflammatory, auto-immune and infectious diseases. Contact us for more information.

We provide access to these platforms as a fee-for-service for the pharmaceutical companies, biotechs as well as academic laboratories which profile new drugs (NCE, peptid, Mab, vaccine)  targeting immuno-related diseases and novel anti-HIV/AIDS therapies.

Main applications :

  • Efficacy studies
  • Combotherapy
  • Stratification of patients
  • PK/PD
  • ADME

TransCure bioServices is located in an international area in France near Geneva (Switzerland) with customers coming from all over the world. We are looking forward to helping you in developing new therapies targeting human diseases.

 

 

 

 

 

EVENTS

 

7-9 November 2016: TransCure bioServices will be glad to meet you at Bio-Europe 2016, Cologne, Germany

8 july 2016 : TransCure bioServices will be glad to meet you at Restoring anticancer immunosurveillance though novel immune checkpoint blockers, Paris, France, organized by Miltenyi Biotec

6-9 June 2016 :  TransCure bioServices will be glad to meet you at BIO US 2016, San Francisco

4-6 April 2016 : TransCure bioServices at Bio-Europe Spring  2016, Stockholm, Sweden

April 2016: TransCure bioServices’ talk  at  Taconic Tour : Advanced Preclinical Models for Immuno-Oncology and Infectious Disease

 

NEWS

May 2015: TransCure bioServices in the magazine "L'expansion". Article (in french)

24 July 2014: € 1.07 million grant to Amal Therapeutics and TransCure bioServices to develop a glioblastoma vaccine using humanized mouse models.
News Realease

01 July 2014: TransCure bioServices raises € 0.7 million.
News Release (English/Français)

View more News...